Evidence map›Paper›PMID 31015255›Full record

ArticleJournal of the American Society of Nephrology : JASN2019

Types of Erythropoietin-Stimulating Agents and Mortality among Patients Undergoing Hemodialysis.

Yusuke Sakaguchi, Takayuki Hamano, Atsushi Wada, Ikuto Masakane

Open access · bronzeAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 4 pooled it
11.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 4 syntheses or guidelines pooled it, 113 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Festschrift in honor of Dr. Jeffrey Hymes.Frontiers in nephrology · 2025
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Observational
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Yusuke SakaguchiCommittee of Renal Data Registry, Japanese Society for Dialysis Therapy, Tokyo, Japan.ORCID 0000-0002-0987-5423
Takayuki HamanoCommittee of Renal Data Registry, Japanese Society for Dialysis Therapy, Tokyo, Japan hamatea@kid.med.osaka-u.ac.jp.
Atsushi WadaCommittee of Renal Data Registry, Japanese Society for Dialysis Therapy, Tokyo, Japan.
Ikuto MasakaneCommittee of Renal Data Registry, Japanese Society for Dialysis Therapy, Tokyo, Japan.
Japanese Society for Dialysis Therapy · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite the widespread use of erythropoietin-stimulating agents (ESAs) to treat anemia in patients undergoing hemodialysis, the relative mortality risks associated with use of different types of ESAs are unknown.

methodsTo compare the mortality risk associated with use of short-acting ESAs versus long-acting ESAs, we conducted a nationwide cohort study of 194,698 hemodialysis patients in Japan who received either a short-acting (epoetin

resultsDuring the 2-year follow-up period, 31,557 deaths occurred. In a multivariable Cox model, long-acting ESA users had a 13% higher rate of deaths compared with short-acting ESA users, a significant difference (

conclusionsAmong patients undergoing hemodialysis, use of long-acting ESAs might be associated with a higher risk of death than use of short-acting ESAs.

Indexed as

AgedAnemiaCause of DeathCohort StudiesDarbepoetin alfaDose-Response Relationship, DrugDrug Administration ScheduleEpoetin AlfaFemaleHumansJapanKidney Failure, ChronicMaleMiddle AgedMultivariate AnalysisPrognosisDarbepoetin alfaEpoetin Alfaerythropoietin-stimulating agentshemodialysismortality

Identifiers

PMID31015255
PMCPMC6551773
OpenAlexW2941651537

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.